Potential nephroprotective effects of l-carnitine against drug-induced nephropathy: a review of literature

Bibliography

• Nolin TD, Himmelfarb J. Drug-induced kidney disease. In: Dipiro JT, editors. Pharmacotherapy, a pathophysiologic approach. 8th edition. Mc Graw Hill companies, Inc, New York; 2011
   Google Scholar
• Naughton CA. Drug-induced nephrotoxicity. Am Fam Physician 2008;78:743-50
   PubMed Web of Science ®Google Scholar
• Perazella MA. Renal vulnerability to drug toxicity. Clin J Am Soc Nephrol 2009;4:1275-83
   PubMed Web of Science ®Google Scholar
• Steiber A, Kerner J, Hoppel CL. Carnitine: a nutritional, biosynthetic, and functional perspective. Mol Aspects Med 2004;25:455-73
   PubMedGoogle Scholar
• Walter JH. l-Carnitine. Arch Dis Child 1996;74:475-8
   PubMed Web of Science ®Google Scholar
• Tanphaichitr V, Leelahagul P. Carnitine metabolism and human carnitine deficiency. Nutrition 1993;9:246-54
   PubMed Web of Science ®Google Scholar
• Calò LA, Vertolli U, Davis PA, Savica V. L carnitine in hemodialysis patients. Hemodial Int 2012;16:428-34
   PubMed Web of Science ®Google Scholar
• Shores NJ, Keeffe EB. Is oral l-acyl-carnitine an effective therapy for hepatic encephalopathy? Review of the literature. Dig Dis Sci 2008;53:2330-3
   PubMed Web of Science ®Google Scholar
• Chapman KA, Gropman A, MacLeod E, et al. Acute management of propionic acidemia. Mol Genet Metab 2011;105:16-25
   PubMed Web of Science ®Google Scholar
• Gahl WA, Bernardini I, Dalakas M, et al. Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest 1988;81:549-60
   PubMed Web of Science ®Google Scholar
• Wadzinski J, Franks R, Roane D, Bayard M. Valproate-associated hyperammonemic encephalopathy. J Am Board Fam Med 2007;20:499-502
   PubMed Web of Science ®Google Scholar
• Leitch A, Williams M. The use of carnitine rather than renal replacement therapy for sodium valproate poisoning. JICS 2010;11:40-3
   Google Scholar
• Plioplys AV, Plioplys S. Amantadine and l-carnitine treatment of Chronic Fatigue Syndrome. Neuropsychobiology 1997;35:16-23
   PubMed Web of Science ®Google Scholar
• Ilias I, Manoli I, Blackman MR, et al. l-Carnitine and acetyl-l-carnitine in the treatment of complications associated with HIV infection and antiretroviral therapy. Mitochondrion 2004;4:163-8
   PubMed Web of Science ®Google Scholar
• Bonner CM, DeBrie KL, Hug G, et al. Effects of parenteral l-carnitine supplementation on fat metabolism and nutrition in premature neonates. J Pediatr 1995;126:287-92
   PubMed Web of Science ®Google Scholar
• Mancuso C, Bates TE, Butterfield DA, et al. Natural antioxidants in Alzheimer's disease. Expert Opin Investig Drugs 2007;16:1921-31
   PubMed Web of Science ®Google Scholar
• Arsenian MA. Carnitine and its derivatives in cardiovascular disease. Prog Cardiovasc Dis 1997;40:265-86
   PubMed Web of Science ®Google Scholar
• Ferrari R, Merli E, Cicchitelli G, et al. Therapeutic effects of l-carnitine and propionyl-l-carnitine on cardiovascular diseases: a review. Ann N Y Acad Sci 2004;1033:79-91
   PubMed Web of Science ®Google Scholar
• Iliceto S, Scrutinio D, Bruzzi P, et al. Effects of l-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the l-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial. J Am Coll Cardiol 1995;26:37-80
   Google Scholar
• Rubin MR, Volek JS, Gomez AL, et al. Safety measures of l-carnitine l-tartrate supplementation in healthy men. J Strength Cond Res 2001;15:486-90
   PubMed Web of Science ®Google Scholar
• Cruciani RA, Dvorkin E, Homel P, et al. Safety, tolerability and symptom outcomes associated with l-carnitine supplementation in patients with cancer, fatigue, and carnitine deficiency: a phase I/II study. J Pain Symptom Manage 2006;32:551-9
   PubMed Web of Science ®Google Scholar
• No authors listed. Study on propionyl-l-carnitine in chronic heart failure. Eur Heart J 1999;20:70-6
   PubMed Web of Science ®Google Scholar
• Ye J, Li J, Yu Y, et al. l-carnitine attenuates oxidant injury in HK-2 cells via ROS-mitochondria pathway. Regul Pept 2010;161:58-66
   PubMed Web of Science ®Google Scholar
• Li JL, Wang QY, Luan HY, et al. Effects of l-carnitine against oxidative stress in human hepatocytes: involvement of peroxisome proliferator-activated receptor alpha. J Biomed Sci 2012;19:32
   PubMed Web of Science ®Google Scholar
• Mutomba MC, Yuan H, Konyavko M, et al. Regulation of the activity of caspases by l-carnitine and palmitoylcarnitine. FEBS Lett 2000;478:19-25
   PubMed Web of Science ®Google Scholar
• Chen HH, Sue YM, Chen CH, et al. Peroxisome proliferator-activated receptor alpha plays a crucial role in l-carnitine anti-apoptosis effect in renal tubular cells. Nephrol Dial Transplant 2009;24:3042-9
   PubMed Web of Science ®Google Scholar
• Arafa HM. Carnitine deficiency aggravates carboplatin nephropathy through deterioration of energy status, oxidant/anti-oxidant balance, and inflammatory endocoids. Toxicology 2008;254:51-60
   PubMed Web of Science ®Google Scholar
• Calvani M, Benatti P, Mancinelli A, et al. Carnitine replacement in end-stage renal disease and hemodialysis. Ann NY Acad Sci 2004;1033:52-66
   PubMed Web of Science ®Google Scholar
• Miguel-Carrasco JL, Mate A, Monserrat MT, et al. The role of inflammatory markers in the cardioprotective effect of l-carnitine in l-NAME-induced hypertension. Am J Hypertens 2008;21:1231-7
   PubMed Web of Science ®Google Scholar
• Tamai I, Ohashi R, Nezu J, et al. Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biol Chem 1998;273:20378-82
   PubMed Web of Science ®Google Scholar
• Marthaler NP, Visarius T, Kupfer A, Lauterburg BH. Increased urinary losses of carnitine during ifosfamide chemotherapy. Cancer Chemother Pharmacol 1999;44:170-2
   PubMed Web of Science ®Google Scholar
• Lancaster CS, Hu C, Franke RM, et al. Cisplatin-induced downregulation of OCTN2 affects carnitine wasting. Clin Cancer Res 2010;16:4789-99
   PubMed Web of Science ®Google Scholar
• Ganapathy ME, Huang W, Rajan DP, et al. Beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. J Biol Chem 2000;275:1699-707
   PubMed Web of Science ®Google Scholar
• Haschke M, Vitins T, Lude S, et al. Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based antineoplastic drugs. Nephrol Dial Transplant 2010;25:426-33
   PubMed Web of Science ®Google Scholar
• Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel) 2010;2:2490-518
   PubMed Web of Science ®Google Scholar
• Chirino YI, Pedraza-Chaverri J. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol 2009;61:223-42
   PubMed Web of Science ®Google Scholar
• Heuberger W, Berardi S, Jacky E, et al. Increased urinary excretion of carnitine in patients treated with cisplatin. Eur J Clin Pharmacol 1998;54:503-8
   PubMed Web of Science ®Google Scholar
• Chang B, Nishikawa M, Sato E, et al. l-Carnitine inhibits cisplatin-induced injury of the kidney and small intestine. Arch Biochem Biophys 2002;405:55-64
   PubMed Web of Science ®Google Scholar
• Sayed-Ahmed MM, Eissa MA, Kenawy SA, et al. Progression of cisplatin-induced nephrotoxicity in a carnitine-depleted rat model. Chemotherapy 2004;50:162-70
   PubMed Web of Science ®Google Scholar
• Aleisa AM, Al-Majed AA, Al-Yahya AA, et al. Reversal of cisplatin-induced carnitine deficiency and energy starvation by propionyl-l-carnitine in rat kidney tissues. Clin Exp Pharmacol Physiol 2007;34:1252-9
   PubMed Web of Science ®Google Scholar
• Cayir K, Karadeniz A, Yildirim A, et al. Protective effect of l-carnitine against cisplatin-induced liver and kidney oxidant injury in rats. Cent Eur J Med 2009;4:184-91
   Web of Science ®Google Scholar
• Tufekci O, Gunes D, Ozogul C, et al. Evaluation of the effect of acetyl l-carnitine on experimental cisplatin nephrotoxicity. Chemotherapy 2009;55:451-9
   PubMed Web of Science ®Google Scholar
• Martinez G, Costantino G, Clementi A, et al. Cisplatin-induced kidney injury in the rat: l-carnitine modulates the relationship between MMP-9 and TIMP-3. Exp Toxicol Pathol 2009;61:183-8
   PubMed Web of Science ®Google Scholar
• Uzunoglu S, Karagol H, Ozpuyan F, et al. Protective effect of l-carnitine versus amifostine against cisplatin-induced nephrotoxicity in rats. Med Oncol 2011;28(Suppl 1):S690-6
   PubMedGoogle Scholar
• Mancinelli A, D'Iddio S, Bisonni R, et al. Urinary excretion of l-carnitine and its short-chain acetyl-l-carnitine in patients undergoing carboplatin treatment. Cancer Chemother Pharmacol 2007;60:19-26
   PubMed Web of Science ®Google Scholar
• Pisano C, Pratesi G, Laccabue D, et al. Paclitaxel and Cisplatin-induced neurotoxicity: a protective role of acetyl-l-carnitine. Clin Cancer Res 2003;9:5756-67
   PubMed Web of Science ®Google Scholar
• Ghirardi O, Lo Giudice P, Pisano C, et al. Acetyl-l-Carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor properties. Anticancer Res 2005;25:2681-7
   PubMed Web of Science ®Google Scholar
• Engle DB, Belisle JA, Gubbels JA, et al. Effect of acetyl-l-carnitine on ovarian cancer cells' proliferation, nerve growth factor receptor (Trk-A and p75) expression, and the cytotoxic potential of paclitaxel and carboplatin. Gynecol Oncol 2009;112:631-6
   PubMed Web of Science ®Google Scholar
• Altun ZS, Gunes D, Aktas S, et al. Protective effects of acetyl-l-carnitine on cisplatin cytotoxicity and oxidative stress in neuroblastoma. Neurochem Res 2010;35:437-43
   PubMed Web of Science ®Google Scholar
• Baumann F, Preiss R. Cyclophosphamide and related anticancer drugs. J Chromatogr B Biomed Sci Appl 2001;764:173-92
   PubMed Web of Science ®Google Scholar
• Ntali S, Bertsias G, Boumpas DT. Cyclophosphamide and lupus nephritis: when, how, for how long? Clin Rev Allergy Immunol 2011;40:181-91
   PubMed Web of Science ®Google Scholar
• Sayed-Ahmed MM. Role of carnitine in cancer chemotherapy-induced multiple organ toxicity. Saudi Pharm J 2010;18:195-206
   Google Scholar
• Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf 2001;24:19-38
   PubMed Web of Science ®Google Scholar
• Woodland C, Ito S, Granvil CP, et al. Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites. Life Sci 2000;68:109-17
   PubMed Web of Science ®Google Scholar
• Nissim I, Horyn O, Daikhin Y, et al. Ifosfamide-induced nephrotoxicity: mechanism and prevention. Cancer Res 2006;66:7824-31
   PubMed Web of Science ®Google Scholar
• Visarius TM, Stucki JW, Lauterburg BH. Inhibition and stimulation of long-chain fatty acid oxidation by chloroacetaldehyde and methylene blue in rats. J Pharmacol Exp Ther 1999;289:820-4
   PubMed Web of Science ®Google Scholar
• Dubourg L, Michoudet C, Cochat P, Baverel G. Human kidney tubules detoxify chloroacetaldehyde, a presumed nephrotoxic metabolite of ifosfamide. J Am Soc Nephrol 2001;12:1615-23
   PubMed Web of Science ®Google Scholar
• Knouzy B, Dubourg L, Baverel G, Michoudet C. Targets of chloroacetaldehyde-induced nephrotoxicity. Toxicol In Vitro 2010;24:99-107
   PubMed Web of Science ®Google Scholar
• Hanly L, Chen N, Rieder M, Koren G. Ifosfamide nephrotoxicity in children: a mechanistic base for pharmacological prevention. Expert Opin Drug Saf 2009;8:155-68
   PubMed Web of Science ®Google Scholar
• Visarius TM, Bahler H, Kupfer A, et al. Thiodiglycolic acid is excreted by humans receiving ifosfamide and inhibits mitochondrial function in rats. Drug Metab Dispos 1998;26:193-6
   PubMed Web of Science ®Google Scholar
• Sayed-Ahmed MM, Aldelemy ML, Hafez MM, Al-Shabanah OA. Inhibition of gene expression of organic cation/carnitine transporter and antioxidant enzymes in oxazaphosphorines-induced acute cardiomyopathic rat models. Oxid Med Cell Longev 2012;2012:452902
   PubMedGoogle Scholar
• Nickel B, Nolte T, Pohl J, et al. The ifosfamide induced nephrotoxicity in rats could be antagonised by l-carnitine without impairment of antitumor responses. Ann Oncol 1998;9(Suppl 2):53-7
   Google Scholar
• Nickel B, Nolte T, Pohl J, et al. Pharmaceutical composition comprising ifosfamide and carnitine. US20030040507A1; 2003
   Google Scholar
• Sayed-Ahmed MM. l-Carnitine attenuates ifosfamide-induced carnitine deficiency and decreased intramitochondrial CoA-SH in rat kidney tissues. J Nephrol 2011;24:490-8
   PubMed Web of Science ®Google Scholar
• Sayed-Ahmed MM. Progression of cyclophosphamide-induced acute renal metabolic damage in carnitine-depleted rat model. Clin Exp Nephrol 2010;14:418-26
   PubMed Web of Science ®Google Scholar
• Graziano F, Bisonni R, Catalano V, et al. Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. Br J Cancer 2002;86:1854-7
   PubMed Web of Science ®Google Scholar
• Blum RH, Carter SK. Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med 1974;80:249-59
   PubMed Web of Science ®Google Scholar
• O'Donnell MP, Michels L, Kasiske B, et al. Adriamycin-induced chronic proteinuria: a structural and functional study. J Lab Clin Med 1985;106:62-7
   PubMedGoogle Scholar
• Fajardo LF, Eltringham JR, Stewart JR, Klauber MR. Adriamycin nephrotoxicity. Lab Invest 1980;43:242-53
   PubMed Web of Science ®Google Scholar
• Mimnaugh EG, Trush MA, Gram TE. A possible role for membrane lipid peroxidation in anthracycline nephrotoxicity. Biochem Pharmacol 1986;35:4327-35
   PubMed Web of Science ®Google Scholar
• Deman A, Ceyssens B, Pauwels M, et al. Altered antioxidant defence in a mouse adriamycin model of glomerulosclerosis. Nephrol Dial Transplant 2001;16:147-50
   PubMed Web of Science ®Google Scholar
• Pal S, Sil PC. A 43 kD protein from the leaves of the herb Cajanus indicus L. modulates doxorubicin induced nephrotoxicity via MAPKs and both mitochondria dependent and independent pathways. Biochimie 2012;94:1356-67
   PubMed Web of Science ®Google Scholar
• Shahbazi F, Dashti-Khavidaki S, Khalili H, Lessan-Pezeshki M. Potential renoprotective effects of silymarin against nephrotoxic drugs: a review of literature. J Pharm Pharm Sci 2012;15:112-23
   PubMed Web of Science ®Google Scholar
• Ayla S, Seckin I, Tanriverdi G, et al. Doxorubicin induced nephrotoxicity: protective effect of nicotinamide. Int J Cell Biol 2011;2011:390238
   PubMedGoogle Scholar
• Venkatesan N, Punithavathi D, Arumugam V. Curcumin prevents adriamycin nephrotoxicity in rats. Br J Pharmacol 2000;129:231-4
   PubMed Web of Science ®Google Scholar
• Ibrahim MA, Ashour OM, Ibrahim YF, et al. Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. Pharmacol Res 2009;60:373-81
   PubMed Web of Science ®Google Scholar
• Boonsanit D, Kanchanapangka S, Buranakarl C. l-carnitine ameliorates doxorubicin-induced nephrotic syndrome in rats. Nephrology (Carlton) 2006;11:313-20
   PubMed Web of Science ®Google Scholar
• Erdogan HM, Citil M, Tuzcu M, et al. The effect of l-carnitine administration on doxorubicine induced hepatoxicity and nephrotoxicity in rabbits. Kafkas Univ Vet Fak Derg 2009;15:733-8
   Web of Science ®Google Scholar
• Radwan RR, Shaban EA, Salem HA, Kenawy SA. Low dose gamma irradiation modifies the effect of l-carnitine, curcumin, garlic powder and green tea extract on doxorubicin-induced nephropathy in rats. Egypt J Hosp Med 2010;40:350-64
   Google Scholar
• Izzedine H, Launay-Vacher V, Karie S, et al. Is low-dose methotrexate nephrotoxic? Case report and review of the literature. Clin Nephrol 2005;64:315-19
   PubMed Web of Science ®Google Scholar
• Green MR, Chamberlain MC. Renal dysfunction during and after high-dose methotrexate. Cancer Chemother Pharmacol 2009;63:599-604
   PubMed Web of Science ®Google Scholar
• Kolli VK, Abraham P, Isaac B, Selvakumar D. Neutrophil infiltration and oxidative stress may play a critical role in methotrexate-induced renal damage. Chemotherapy 2009;55:83-90
   PubMed Web of Science ®Google Scholar
• Devrim E, Cetin R, Kilicoglu B, et al. Methotrexate causes oxidative stress in rat kidney tissues. Ren Fail 2005;27:771-3
   PubMed Web of Science ®Google Scholar
• Sener G, Eksioglu-Demiralp E, Cetiner M, et al. l-Carnitine ameliorates methotrexate-induced oxidative organ injury and inhibits leukocyte death. Cell Biol Toxicol 2006;22:47-60
   PubMed Web of Science ®Google Scholar
• Mathew TH. Drug-induced renal disease. Med J Aust 1992;156:724-8
   PubMed Web of Science ®Google Scholar
• Balakumar P, Rohilla A, Thangathirupathi A. Gentamicin-induced nephrotoxicity: do we have a promising therapeutic approach to blunt it? Pharmacol Res 2010;62:179-86
   PubMed Web of Science ®Google Scholar
• Lopez-Novoa JM, Quiros Y, Vicente L, et al. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int 2011;79:33-45
   PubMed Web of Science ®Google Scholar
• Martinez-Salgado C, Lopez-Hernandez FJ, Lopez-Novoa JM. Glomerular nephrotoxicity of aminoglycosides. Toxicol Appl Pharmacol 2007;223:86-98
   PubMed Web of Science ®Google Scholar
• Ali BH. Agents ameliorating or augmenting experimental gentamicin nephrotoxicity: some recent research. Food Chem Toxicol 2003;41:1447-52
   PubMed Web of Science ®Google Scholar
• Nasiri-Toosi Z, Dashti-Khavidaki S, Khalili H, Lessan-Pezeshki M. A review of the potential protective effects of pentoxifylline against drug-induced nephrotoxicity. Eur J Clin Pharmacol 2012; published online22 November2012; doi:10.1007/s00228-012-1452-x
   PubMed Web of Science ®Google Scholar
• Kopple JD, Ding H, Letoha A, et al. l-carnitine ameliorates gentamicin-induced renal injury in rats. Nephrol Dial Transplant 2002;17:2122-31
   PubMed Web of Science ®Google Scholar
• Kart A, Yapar K, Karapehlivan M, et al. Effects of l-Carnitine on kidney histopathology, plasma and tissue total sialic acid, malondialdehyde and glutathione concentrations in response to gentamicin administration in Balb/C mice. Revue Méd Vét 2006;154:179-84
   Google Scholar
• Al-Shabanah OA, Aleisa AM, Al-Yahya AA, et al. Increased urinary losses of carnitine and decreased intramitochondrial coenzyme A in gentamicin-induced acute renal failure in rats. Nephrol Dial Transplant 2010;25:69-76
   PubMed Web of Science ®Google Scholar
• Tedesco D, Haragsim L. Cyclosporine: a review. J Transplant 2012; published 2012; doi:10.1155/2012/230386
   PubMedGoogle Scholar
• O'Connell S, Tuite N, Slattery C, et al. Cyclosporine A–induced oxidative stress in human renal mesangial cells: a role for ERK 1/2 MAPK signaling. Toxicol Sci 2012;126:101-13
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Perico N, Gaspari F, Remuzzi G. Nephrotoxic aspects of cyclosporine. Transplant Proc 2004;36:234S-9S
   PubMed Web of Science ®Google Scholar
• Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009;4:481-508
   PubMed Web of Science ®Google Scholar
• Parra Cid T, Conejo Garcia JR, Carballo Alvarez F, de Arriba G. Antioxidant nutrients protect against cyclosporine A nephrotoxicity. Toxicology 2003;189:99-111
   PubMed Web of Science ®Google Scholar
• Calvani M, Mosconi L. Use of l-carnitine and its derivatives for reducing the toxic effects of cyclosporine-A and others immunosuppressant. EP0722724B1; 1999
   Google Scholar
• Cavazza C. Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents. US7897641B2; 2011
   Google Scholar
• Bertelli A, Giovannini L, Palla R, et al. Protective effect of l-propionylcarnitine on cyclosporine-induced nephrotoxicity. Drugs Exp Clin Res 1995;21:221-8
   PubMedGoogle Scholar
• Giovannini L, Palla R, Bertelli AA, et al. Cyclosporine nephrotoxicity evaluated by tissue calcium deposition and tubular enzymes is prevented by l-propionylcarnitine in isolated perfused rat kidney. Transplant Proc 1996;28:3122-5
   PubMed Web of Science ®Google Scholar
• Giovannini L, Migliori M, Taccola D, et al. Acute CYA-induced ATP depletion is prevented by pretreatment with l-propionylcarnitine in isolated and perfused rat kidney. Transplant Proc 1998;30:2026-7
   PubMed Web of Science ®Google Scholar
• Giovannini L, Migliori M, De Pietro S, et al. l-propionyl carnitine reduces toxicity correlated to cyclosporine-induced intracellular ATP concentrations. Drugs Exp Clin Res 1999;25:173-7
   PubMedGoogle Scholar
• Longoni B, Giovannini L, Migliori M, et al. Cyclosporine-induced lipid peroxidation and propionyl carnitine protective effect. Int J Tissue React 1999;21:7-11
   PubMedGoogle Scholar
• Giovannini L, Migliori M, Origlia N, et al. Acute cyclosporine A nephrotoxicity: protective effect of l-propionylcarnitine on lipid peroxidation in isolated and perfused rat kidney (IPRK). Br J Pharmacol 2001;133(Suppl):S Meeting Abstract: 253P
   Google Scholar
• Origlia N, Migliori M, Panichi V, et al. l-propionyl carnitine protects rat kidneys against cyclosporine-A induced lipid peroxidation invivo. Nephrol Dial Transplant 2002;17:172-8
   PubMedGoogle Scholar
• Origlia N, Migliori M, Panichi V, et al. Protective effect of l-propionylcarnitine in chronic cyclosporine-a induced nephrotoxicity. Biomed Pharmacother 2006;60:77-81
   PubMed Web of Science ®Google Scholar
• Fattorossi A, Biselli R, Casciaro A, et al. Regulation of normal human polyrnorphonuclear leucocytes by carnitine. Mediators Inflamm 1993;2:S37-41
   PubMedGoogle Scholar
• Winter BK, Fiskum G, Gallo LL. Effects of l-carnitine on serum triglyceride and cytokine levels in rat models of cachexia and septic shock. Br J Cancer 1995;72:1173-9
   PubMed Web of Science ®Google Scholar
• Athanassakis I, Mouratidou M, Sakka P, et al. l-carnitine modifies the humoral immune response in mice after in vitro or in vivo treatment. Int Immunopharmacol 2001;1:1813-22
   PubMed Web of Science ®Google Scholar
• Alesci S, De Martino MU, Mirani M, et al. l-carnitine: A nutritional modulator of glucocorticoid receptor functions. Faseb J 2003;17:1553-5
   PubMed Web of Science ®Google Scholar
• Fortin G, Yurchenko K, Collette C, et al. l-carnitine, a diet component and organic cation transporter OCTN ligand, displays immunosuppressive properties and abrogates intestinal inflammation. Clin Exp Immunol 2009;156:161-71
   PubMed Web of Science ®Google Scholar
• De Simone C, Ferrari M, Meli D, et al. Reversibility by l-carnitine of immunosuppression induced by an emulsion of soya bean oil, glycerol and egg lecithin. Arzneimittelforschung 1982;32:1485-8
   PubMed Web of Science ®Google Scholar
• Kouttab NM, De Simone C. Modulation of cytokine production by carnitine. Mediators Inflamm 1993;2:S25-8
   PubMed Web of Science ®Google Scholar
• De Simone C, Famularo G, Tzantzoglou S, et al. Carnitine depletion in peripheral blood mononuclear cells from patients with AIDS: effect of oral l-carnitine. Aids 1994;8:655-60
   PubMed Web of Science ®Google Scholar
• Gleeson TG, Bulugahapitiya S. Contrast-induced nephropathy. AJR Am J Roentgenol 2004;183:1673-89
   PubMed Web of Science ®Google Scholar
• Rudnick MR, Kesselheim A, Goldfarb S. Contrast-induced nephropathy: how it develops, how to prevent it. Cleve Clin J Med 2006;73:75-80. 83-7
   PubMed Web of Science ®Google Scholar
• Jabbari M, Mooraki A, Jenabi A, et al. l-carnitine ameliorates contrast media-induced renal injury in rats. Nephrol Dial Transplant 2007;22:vi245-vi50
   Google Scholar
• Nephroprotective effects of Carnitine and (PDE5) inhibitor agent against Contrast Media-induced Nephropathy (CMN). 2012. Available from: http://clinicaltrials.gov/ct2/show/NCT01564303
   Google Scholar
• Delaney CE, Hopkins SP, Addison CL. Supplementation with l-carnitine does not reduce the efficacy of epirubicin treatment in breast cancer cells. Cancer Lett 2007;252:195-207
   PubMed Web of Science ®Google Scholar
• Pisano C, Vesci L, Milazzo FM, et al. Metabolic approach to the enhancement of antitumor effect of chemotherapy: a key role of acetyl-l-carnitine. Clin Cancer Res 2010;16:3944-53
   PubMed Web of Science ®Google Scholar
• Huang H, Liu N, Guo H, et al. l-carnitine is an endogenous HDAC inhibitor selectively inhibiting cancer cell growth in vivo and in vitro. PLoS One 2012;7:e49062
   PubMed Web of Science ®Google Scholar
• Bonventre JV, Vaidya VS, Schmouder R, et al. Next-generation biomarkers for detecting kidney toxicity. Nat Biotechnol 2010;28:436-40
   PubMed Web of Science ®Google Scholar
• Hosohata K, Ando H, Fujiwara Y, Fujimura A. Vanin-1: a potential biomarker for nephrotoxicant-induced renal injury. Toxicology 2011;290:82-8
   PubMed Web of Science ®Google Scholar
• Waring WS, Moonie A. Earlier recognition of nephrotoxicity using novel biomarkers of acute kidney injury. Clin Toxicol (Phila) 2011;49:720-8
   PubMed Web of Science ®Google Scholar
• Fuchs TC, Hewitt P. Biomarkers for drug-induced renal damage and nephrotoxicity-an overview for applied toxicology. Aaps J 2011;13:615-31
   PubMed Web of Science ®Google Scholar